| Year |
Citation |
Score |
| 2023 |
Lopez-Cuina M, Guérin P, Dutheil N, Martin C, Lasserre TL, Fernagut PO, Meissner WG, Bezard E. GRK2-Targeted Knockdown as Therapy for Multiple System Atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 37093618 DOI: 10.1002/mds.29422 |
0.409 |
|
| 2023 |
Decourt M, Balado E, Francheteau M, Solinas M, Benoît-Marand M, Fernagut PO. Premorbid performances determine the deleterious effects of nigrostriatal degeneration and pramipexole on behavioural flexibility. Npj Parkinson's Disease. 9: 31. PMID 36859454 DOI: 10.1038/s41531-023-00475-3 |
0.366 |
|
| 2021 |
Mallet D, Dufourd T, Decourt M, Carcenac C, Bossù P, Verlin L, Fernagut PO, Benoit-Marand M, Spalletta G, Barbier EL, Carnicella S, Sgambato V, Fauvelle F, Boulet S. A metabolic biomarker for early stage of Parkinson's disease in patients and animal models. The Journal of Clinical Investigation. PMID 34914634 DOI: 10.1172/JCI146400 |
0.372 |
|
| 2021 |
Theis H, Probst C, Fernagut PO, van Eimeren T. Unlucky punches: the vulnerability-stress model for the development of impulse control disorders in Parkinson's disease. Npj Parkinson's Disease. 7: 112. PMID 34880241 DOI: 10.1038/s41531-021-00253-z |
0.32 |
|
| 2021 |
Bassil F, Delamarre A, Canron MH, Dutheil N, Vital A, Négrier-Leibreich ML, Bezard E, Fernagut PO, Meissner WG. Impaired brain insulin signalling in Parkinson's disease. Neuropathology and Applied Neurobiology. PMID 34405431 DOI: 10.1111/nan.12760 |
0.514 |
|
| 2021 |
Decourt M, Jiménez-Urbieta H, Benoit-Marand M, Fernagut PO. Neuropsychiatric and Cognitive Deficits in Parkinson's Disease and Their Modeling in Rodents. Biomedicines. 9. PMID 34204380 DOI: 10.3390/biomedicines9060684 |
0.369 |
|
| 2021 |
Sun X, Yu X, Zhang L, Zhao W, Wang M, Zhang Y, Li X, Gao R, Breger LS, Dovero S, Porras G, Fernagut PO, Dehay B, Bezard E, Qin C. Comparison of the expression and toxicity of AAV2/9 carrying the human A53T α-synuclein gene in presence or absence of WPRE. Heliyon. 7: e06302. PMID 33665452 DOI: 10.1016/j.heliyon.2021.e06302 |
0.507 |
|
| 2021 |
Fridjonsdottir E, Shariatgorji R, Nilsson A, Vallianatou T, Odell LR, Schembri LS, Svenningsson P, Fernagut PO, Crossman AR, Bezard E, Andrén PE. Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Science Advances. 7. PMID 33523980 DOI: 10.1126/sciadv.abe5948 |
0.534 |
|
| 2020 |
Deffains M, Canron MH, Teil M, Li Q, Dehay B, Bezard E, Fernagut PO. L-DOPA regulates α-synuclein accumulation in experimental parkinsonism. Neuropathology and Applied Neurobiology. PMID 33275784 DOI: 10.1111/nan.12678 |
0.594 |
|
| 2020 |
Yu Z, Shi M, Stewart T, Fernagut PO, Huang Y, Tian C, Dehay B, Atik A, Yang D, De Giorgi F, Ichas F, Canron MH, Ceravolo R, Frosini D, Kim HJ, et al. Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. Brain : a Journal of Neurology. PMID 32428221 DOI: 10.1093/Brain/Awaa110 |
0.416 |
|
| 2020 |
Lopez-Cuina M, Guerin PA, Canron MH, Delamarre A, Dehay B, Bezard E, Meissner WG, Fernagut PO. Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32291831 DOI: 10.1002/Mds.28034 |
0.616 |
|
| 2019 |
Meissner WG, Fernagut PO, Dehay B, Péran P, Traon AP, Foubert-Samier A, Lopez Cuina M, Bezard E, Tison F, Rascol O. Multiple System Atrophy: Recent Developments and Future Perspectives. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31692132 DOI: 10.1002/Mds.27894 |
0.593 |
|
| 2019 |
Arotcarena ML, Bourdenx M, Dutheil N, Thiolat ML, Doudnikoff E, Dovero S, Ballabio A, Fernagut PO, Meissner WG, Bezard E, Dehay B. Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. Jci Insight. 4. PMID 31434803 DOI: 10.1172/Jci.Insight.129719 |
0.632 |
|
| 2019 |
Fernagut PO. Dopamine and eating behavior disorders in Parkinson's disease: A complex recipe. Movement Disorders : Official Journal of the Movement Disorder Society. 34: 767-768. PMID 31206832 DOI: 10.1002/Mds.27703 |
0.411 |
|
| 2019 |
Li Q, Fernagut PO, Bezard E. l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31083822 DOI: 10.1002/Mds.27715 |
0.548 |
|
| 2018 |
Jiménez-Urbieta H, Gago B, Quiroga-Varela A, Rodríguez-Chinchilla T, Merino-Galán L, Oregi A, Belloso-Iguerategui A, Delgado-Alvarado M, Navalpotro-Gómez I, Marin C, Fernagut PO, Rodríguez-Oroz MC. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease. Neurobiology of Aging. 75: 126-135. PMID 30572183 DOI: 10.1016/J.Neurobiolaging.2018.11.021 |
0.499 |
|
| 2018 |
Lopez-Cuina M, Fernagut PO, Canron MH, Vital A, Lannes B, De Paula AM, Streichenberger N, Guehl D, Damier P, Eusebio A, Houeto JL, Tison F, Tranchant C, Viallet F, Witjas T, et al. Deep brain stimulation does not enhance neuroinflammation in multiple system atrophy. Neurobiology of Disease. 118: 155-160. PMID 30026036 DOI: 10.1016/J.Nbd.2018.07.016 |
0.453 |
|
| 2018 |
Al Sagheer T, Haida O, Balbous A, Francheteau M, Matas E, Fernagut PO, Jaber M. Motor impairments correlate with social deficits and restricted neuronal loss in an environmental model of autism. The International Journal of Neuropsychopharmacology. PMID 29762671 DOI: 10.1093/Ijnp/Pyy043 |
0.334 |
|
| 2018 |
Marques A, Durif F, Fernagut PO. Impulse control disorders in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 29511827 DOI: 10.1007/S00702-018-1870-8 |
0.497 |
|
| 2017 |
Bassil F, Guerin PA, Dutheil N, Li Q, Klugmann M, Meissner WG, Bezard E, Fernagut PO. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28556404 DOI: 10.1002/Mds.27041 |
0.646 |
|
| 2017 |
Bastide MF, Glangetas C, Doudnikoff E, Li Q, Bourdenx M, Fernagut PO, Dumont ÉC, Georges F, Bézard E. Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia. Scientific Reports. 7: 2348. PMID 28539659 DOI: 10.1038/S41598-017-02572-9 |
0.634 |
|
| 2017 |
Soria FN, Engeln M, Martinez-Vicente M, Glangetas C, López-González MJ, Dovero S, Dehay B, Normand E, Vila M, Favereaux A, Georges F, Lo Bianco C, Bezard E, Fernagut PO. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Human Molecular Genetics. PMID 28520872 DOI: 10.1093/Hmg/Ddx120 |
0.764 |
|
| 2017 |
Laurens B, Vergnet S, Lopez MC, Foubert-Samier A, Tison F, Fernagut PO, Meissner WG. Multiple System Atrophy - State of the Art. Current Neurology and Neuroscience Reports. 17: 41. PMID 28378233 DOI: 10.1007/S11910-017-0751-0 |
0.433 |
|
| 2017 |
Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, Gulyani S, Kapogiannis D, Fernagut PO, Meissner WG. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain : a Journal of Neurology. PMID 28334990 DOI: 10.1093/Brain/Awx044 |
0.52 |
|
| 2017 |
Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. The Lancet. Neurology. 16: 238-250. PMID 28229895 DOI: 10.1016/S1474-4422(17)30004-2 |
0.609 |
|
| 2016 |
Bassil F, Fernagut PO, Bezard E, Pruvost A, Leste-Lasserre T, Hoang QQ, Ringe D, Petsko GA, Meissner WG. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proceedings of the National Academy of Sciences of the United States of America. PMID 27482103 DOI: 10.1073/Pnas.1609291113 |
0.581 |
|
| 2016 |
Engeln M, Ansquer S, Dugast E, Bezard E, Belin D, Fernagut PO. Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy. Neuropharmacology. PMID 27216859 DOI: 10.1016/J.Neuropharm.2016.05.013 |
0.782 |
|
| 2016 |
Dehay B, Decressac M, Bourdenx M, Guadagnino I, Fernagut PO, Tamburrino A, Bassil F, Meissner WG, Bezard E. Targeting α-synuclein: Therapeutic options. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26926119 DOI: 10.1002/Mds.26568 |
0.617 |
|
| 2016 |
Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiology of Disease. PMID 26804029 DOI: 10.1016/J.Nbd.2016.01.016 |
0.638 |
|
| 2015 |
Perez-Lloret S, Flabeau O, Fernagut PO, Pavy-Le Traon A, Rey MV, Foubert-Samier A, Tison F, Rascol O, Meissner WG. Current Concepts in the Treatment of Multiple System Atrophy. Movement Disorders Clinical Practice. 2: 6-16. PMID 30363880 DOI: 10.1002/Mdc3.12145 |
0.339 |
|
| 2015 |
Bassil F, Monvoisin A, Canron MH, Vital A, Meissner WG, Tison F, Fernagut PO. Region-Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26260627 DOI: 10.1002/Mds.26329 |
0.376 |
|
| 2015 |
Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology. PMID 26209473 DOI: 10.1016/J.Pneurobio.2015.07.002 |
0.765 |
|
| 2015 |
Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Dutheil N, Vollenweider I, Baud L, Piron C, Grouthier V, Boraud T, Porras G, Li Q, Baekelandt V, Scheller D, ... ... Fernagut PO, et al. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. Acta Neuropathologica Communications. 3: 46. PMID 26205255 DOI: 10.1186/S40478-015-0222-2 |
0.787 |
|
| 2014 |
Bastide MF, de la Crompe B, Doudnikoff E, Fernagut PO, Gross CE, Mallet N, Boraud T, Bézard E. Inhibiting Lateral Habenula Improves L-DOPA-induced Dyskinesia. Biological Psychiatry. PMID 25442003 DOI: 10.1016/J.Biopsych.2014.08.022 |
0.535 |
|
| 2014 |
Engeln M, Bastide MF, Toulmé E, Dehay B, Bourdenx M, Doudnikoff E, Li Q, Gross CE, Boué-Grabot E, Pisani A, Bezard E, Fernagut PO. Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-Dopa-Induced Dyskinesia. Biological Psychiatry. PMID 25146322 DOI: 10.1016/J.Biopsych.2014.07.007 |
0.754 |
|
| 2014 |
Engeln M, De Deurwaerdère P, Li Q, Bezard E, Fernagut PO. Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. Cerebral Cortex (New York, N.Y. : 1991). PMID 24770706 DOI: 10.1093/cercor/bhu076 |
0.759 |
|
| 2014 |
Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Pavy-Le Traon A, Rascol O, Foubert-Samier A, Tison F, Meissner WG. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiology of Disease. 67: 133-9. PMID 24727096 DOI: 10.1016/J.Nbd.2014.03.021 |
0.609 |
|
| 2014 |
Vitrac C, Péron S, Frappé I, Fernagut PO, Jaber M, Gaillard A, Benoit-Marand M. Dopamine control of pyramidal neuron activity in the primary motor cortex via D2 receptors. Frontiers in Neural Circuits. 8: 13. PMID 24616667 DOI: 10.3389/Fncir.2014.00013 |
0.36 |
|
| 2014 |
Bassil F, Fernagut PO, Bezard E, Meissner WG. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Progress in Neurobiology. 118: 1-18. PMID 24582776 DOI: 10.1016/J.Pneurobio.2014.02.005 |
0.549 |
|
| 2014 |
Flabeau O, Meissner WG, Ozier A, Berger P, Tison F, Fernagut PO. Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 388-95. PMID 24442757 DOI: 10.1002/Mds.25804 |
0.346 |
|
| 2014 |
Bezard E, Fernagut PO. Premotor parkinsonism models. Parkinsonism & Related Disorders. 20: S17-9. PMID 24262174 DOI: 10.1016/S1353-8020(13)70007-5 |
0.55 |
|
| 2014 |
Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bezard E, Vila M. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Annals of Neurology. 75: 351-62. PMID 24243558 DOI: 10.1002/Ana.24066 |
0.644 |
|
| 2014 |
Bastide MF, Dovero S, Charron G, Porras G, Gross CE, Fernagut PO, Bézard E. Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia. Neurobiology of Disease. 62: 179-92. PMID 24103779 DOI: 10.1016/J.Nbd.2013.09.020 |
0.461 |
|
| 2013 |
Engeln M, Fasano S, Ahmed SH, Cador M, Baekelandt V, Bezard E, Fernagut PO. Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Annals of Neurology. 74: 140-4. PMID 23494678 DOI: 10.1002/Ana.23881 |
0.781 |
|
| 2013 |
Engeln M, Ahmed SH, Vouillac C, Tison F, Bezard E, Fernagut PO. Reinforcing properties of Pramipexole in normal and parkinsonian rats. Neurobiology of Disease. 49: 79-86. PMID 22940424 DOI: 10.1016/J.Nbd.2012.08.005 |
0.749 |
|
| 2012 |
Fernagut PO, Vital A, Canron MH, Tison F, Meissner WG. Ambiguous mechanisms of dysphagia in multiple system atrophy. Brain : a Journal of Neurology. 135: e205; author reply e. PMID 21824966 DOI: 10.1093/Brain/Awr185 |
0.349 |
|
| 2011 |
Fantin M, Morari M, Tison F, Fernagut PO. NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid. Neurological Research. 33: 444-7. PMID 21535946 DOI: 10.1179/1743132810Y.0000000002 |
0.333 |
|
| 2011 |
Leger F, Fernagut PO, Canron MH, Léoni S, Vital C, Tison F, Bezard E, Vital A. Protein aggregation in the aging retina. Journal of Neuropathology and Experimental Neurology. 70: 63-8. PMID 21157377 DOI: 10.1097/Nen.0B013E31820376Cc |
0.493 |
|
| 2010 |
Fernagut PO, Li Q, Dovero S, Chan P, Wu T, Ravenscroft P, Hill M, Chen Z, Bezard E. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. Plos One. 5: e14053. PMID 21124922 DOI: 10.1371/Journal.Pone.0014053 |
0.597 |
|
| 2010 |
Fernagut PO, Barraud Q, Bezard E, Ghorayeb I, Tison F. Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonism. Neurological Research. 32: 1050-3. PMID 20810027 DOI: 10.1179/016164110X12807570509934 |
0.631 |
|
| 2009 |
Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. The Lancet. Neurology. 8: 1140-9. PMID 19909912 DOI: 10.1016/S1474-4422(09)70287-X |
0.604 |
|
| 2009 |
Vital A, Fernagut PO, Canron MH, Joux J, Bezard E, Martin-Negrier ML, Vital C, Tison F. The nigrostriatal pathway in Creutzfeldt-Jakob disease. Journal of Neuropathology and Experimental Neurology. 68: 809-15. PMID 19535991 DOI: 10.1097/Nen.0B013E3181Abdae8 |
0.604 |
|
| 2008 |
Chou AP, Maidment N, Klintenberg R, Casida JE, Li S, Fitzmaurice AG, Fernagut PO, Mortazavi F, Chesselet MF, Bronstein JM. Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome. The Journal of Biological Chemistry. 283: 34696-703. PMID 18818210 DOI: 10.1074/Jbc.M802210200 |
0.475 |
|
| 2005 |
Fleming SM, Fernagut PO, Chesselet MF. Genetic mouse models of parkinsonism: strengths and limitations. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 2: 495-503. PMID 16389313 DOI: 10.1602/Neurorx.2.3.495 |
0.517 |
|
| 2005 |
Fernagut PO, Ghorayeb I, Diguet E, Tison F. In vivo models of multiple system atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. 20: S57-63. PMID 16092092 DOI: 10.1002/Mds.20541 |
0.43 |
|
| 2005 |
Chesselet MF, Fernagut PO, Fleming S. Parkinson's disease models: From toxins to genes Drug Discovery Today: Disease Models. 2: 299-303. DOI: 10.1016/J.Ddmod.2005.11.008 |
0.469 |
|
| 2004 |
Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 9434-40. PMID 15496679 DOI: 10.1523/Jneurosci.3080-04.2004 |
0.407 |
|
| 2004 |
Fernagut PO, Chesselet MF. Alpha-synuclein and transgenic mouse models. Neurobiology of Disease. 17: 123-30. PMID 15474350 DOI: 10.1016/J.Nbd.2004.07.001 |
0.404 |
|
| 2004 |
Zhu C, Vourc'h P, Fernagut PO, Fleming SM, Lacan S, Dicarlo CD, Seaman RL, Chesselet MF. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. The Journal of Comparative Neurology. 478: 418-26. PMID 15384065 DOI: 10.1002/Cne.20305 |
0.396 |
|
| 2004 |
Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. The European Journal of Neuroscience. 19: 3266-76. PMID 15217383 DOI: 10.1111/j.0953-816X.2004.03372.x |
0.529 |
|
| 2004 |
Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, Chesselet MF. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Experimental Neurology. 187: 418-29. PMID 15144868 DOI: 10.1016/J.Expneurol.2004.01.023 |
0.399 |
|
| 2004 |
Diguet E, Fernagut PO, Normand E, Centelles L, Mulle C, Tison F. Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history. Neurobiology of Disease. 15: 667-75. PMID 15056475 DOI: 10.1016/J.Nbd.2003.12.010 |
0.351 |
|
| 2003 |
Stefanova N, Puschban Z, Fernagut PO, Brouillet E, Tison F, Reindl M, Jellinger KA, Poewe W, Wenning GK. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathologica. 106: 157-66. PMID 12764627 DOI: 10.1007/S00401-003-0717-Y |
0.321 |
|
| Show low-probability matches. |